A phase I open-label trial (NCT05620342) is currently evaluating the safety and preliminary efficacy of iC9-GD2.CAR.IL-15 T cells in up to 24 patients with platinum-refractory or PD-L1 inhibitor-resistant ES-SCLC or stage IV NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.